Ignite Creation Date:
2024-05-06 @ 1:21 AM
Last Modification Date:
2024-10-26 @ 11:02 AM
Study NCT ID:
NCT01788072
Status:
COMPLETED
Last Update Posted:
2018-01-25
First Post:
2013-02-07
Brief Title:
INtranasal OXyTocin for the Treatment of Autism Spectrum Disorders
Sponsor:
Evdokia Anagnostou
Organization:
Anagnostou Evdokia MD
Study Overview
Official Title:
INtranasal OXyTocin for the Treatment of Autism Spectrum Disorders ASD
Status:
COMPLETED
Status Verified Date:
2018-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
INOXT
Brief Summary:
There is substantial evidence from animal model and healthy control data that oxytocin is involved in the modulation of social cognition In addition recent genetics and plasma level studies suggest a possible role for oxytocin in the pathophysiology of Autism Spectrum Disorders ASD As a large number of children with ASD are transitioning into adulthood and will likely require treatment the lack of data to make meaningful treatment recommendations to facilitate adult living is an urgent issue This study will examine the effect of intranasal oxytocin IN-OXT on social function in adults with ASD It is hypothesized that IN-OXT will be superior to placebo in improving social function by the end of study treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None